EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors

Laura Veronica Budău iD, Cristina Pop iD, Cristina Mogoșan iD

Pharmaceuticals · 26.06.2025 · 18 (7) · 959

DOI: 10.3390/ph18070959 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 26.06.2025. Verfasst von Laura Veronica Budău und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology and Physiopathology, Faculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Nap…. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer remains a major global health burden driven by complex biological mechanisms, and while targeted therapies like tyrosine kinase inhibitors (TKIs) have revolutionized treatment, their efficacy and safety are significantly influenced by drug–drug interactions (DDIs). Tyrosine-kinase receptors (RTKs) regulate critical cellular processes, and their dysregulation through mutations or overexpression drives oncogenesis, with TKIs designed to inhibit these aberrant signaling pathways by targeting RTK phosphorylation. Pharmacokinetic DDIs can critically impact the efficacy and safety of TKIs such as erlotinib, gefitinib, and pazopanib by affecting their absorption, distribution, and metabolism. The modification of pH can influence drug absorption; furthermore, the inhibition or induction of metabolizing enzymes may affect biotransformation, while distribution can be altered through the modulation of transmembrane transporters. Additionally, ensuring quality of life during TKI treatment requires vigilant monitoring and management of adverse events, which range from mild (e.g., rash, diarrhea, fatigue) to severe (e.g., hepatotoxicity, cardiotoxicity). Drug-specific toxicities, such as hyperlipidemia with lorlatinib or visual disturbances with crizotinib, must be assessed using specific criteria, with dose adjustments and supportive care tailored to individual patient responses. Thus, optimal TKI therapy relies on managing drug interactions through multidisciplinary care, monitoring, and patient education to ensure safety and treatment efficacy.

Schlagwörter

Stichwörter der Autor:innen

cancerdrug therapy optimizationdrug–drug interactionssafety of TKIstyrosine kinase inhibitors (TKIs)

Autor:innen und Institutionen

  • Department of Pharmacology, Physiology and Physiopathology, Faculty of Pharmacy, Iuliu Hatieganu University of Medicine and Pharmacy, 400347 Cluj-Napoca, Romania.
  • Amethyst Radiotherapy Center Clinic, 407280 Florești, Romania.

ORCID-Profile: Laura Veronica Budău, Cristina Pop, Cristina Mogoșan

Zitieren

APA

Budău, L. V., Pop, C., & Mogoșan, C. (2025). Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors. Pharmaceuticals, 18(7), 959. https://doi.org/10.3390/ph18070959

Vancouver

Budău LV, Pop C, Mogoșan C. Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors. Pharmaceuticals. 2025;18(7):959. doi:10.3390/ph18070959

BibTeX
@article{Budu2025,
  author = {Budău, Laura Veronica and Pop, Cristina and Mogoșan, Cristina},
  title = {Beyond the Basics: Exploring Pharmacokinetic Interactions and Safety in Tyrosine-Kinase Inhibitor Oral Therapy for Solid Tumors},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {7},
  pages = {959},
  doi = {10.3390/ph18070959}
}
Kostenlos starten →